A study led by Dr. Louise Kuhn, professor of Epidemiology at Columbia’s Mailman School of Public Health, evaluated whether HIV-infected children in South Africa who had achieved viral suppression with one antiretroviral treatment could transition to efavirenz-based therapy, the recommended drug for children older than 3 years, without risk of viral failure. Dr. Kuhn and colleagues reported that the treatment program resulted in excellent sustained virological control. Findings are published in the November 3 issue of JAMA.
[Photo: Dr. Louise Kuhn]
For infants and young children, ritonavir-boosted lopinavir-based therapy had been recommended as first-line antiretroviral therapy, while efavirenz was the suggested first-line regimen in adults and older children. Advantages of the latter regimen are a once-a-day dose regimen, a simplified co-treatment for tuberculosis, and a similar dosing arrangement for adults and children. However, there had been concerns about the possibility of less effectiveness of efavirenz in children exposed to nevirapine for prevention of mother-to-child transmission. This is because efavirenz and nevirapine are in the same drug class and the majority of children who become infected despite exposure to nevirapine used for prevention have mutations in their virus that usually predict resistance to this drug class.
The study, conducted at Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa, included HIV-infected children 3 years of age or older who were successfully suppressed on treatment with ritonavir-boosted lopinavir, that is, the child’s virus in their blood was undetectable using standard tests. All of these children and their mothers had also received nevirapine at birth in an unsuccessful attempt to prevent mother-to-child HIV transmission.The researchers followed the children for up to 48 weeks.
The researchers found that switching to efavirenz-based therapy compared with continuing ritonavir-boosted lopinavir-based therapy did not result in significantly higher rates of viral failure.
“Until now, there had been little guidance available as to what clinicians ought to do when confronted with a child older than 3 years who has begun treatment with ritonavir-boosted lopinavir,” said Dr. Kuhn, who is also part of Columbia’s Sergievsky Center. “As a result, it has been left to individual interpretation, and there are anecdotal reports of clinicians switching to efavirenz in the absence of data to support such a practice. This study provides evidence for the safety and efficacy of switching to efavirenz, the recommended drug for children older than 3 years, among children with viral suppression.”
The study was supported by a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The authors reported no conflicts of interest.